Trial Profile
The Additive Effect of Vitamin K Supplementation and Bisphosphonate on Fracture Risk in Post-menopausal Osteoporosis.
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 02 Feb 2022
Price :
$35
*
At a glance
- Drugs Menatetrenone (Primary) ; Phytomenadione (Primary) ; Alendronic acid; Bisphosphonates
- Indications Metabolic bone diseases; Postmenopausal osteoporosis
- Focus Therapeutic Use
- Acronyms VITKANDOP
- 17 Oct 2020 Status changed from active, no longer recruiting to completed.
- 12 Feb 2020 Planned End Date changed from 1 Mar 2020 to 31 Mar 2020.
- 12 Feb 2020 Planned primary completion date changed from 1 Mar 2020 to 31 Mar 2020.